	US 12,274,789 B2
	Oral compositions comprising methylprednisolone sodium succinate
Tsampikos Dimitrios Panagiotopoulos, Marousi (GR); and Soultana Tziala, Artemida (GR)
Assigned to LABOMED PHARMACEUTICAL COMPANY S.A., Koropi (GR)
Appl. No. 17/251,784
Filed by LABOMED PHARMACEUTICAL COMPANY S.A., Attica (GR)
PCT Filed Jun. 18, 2019, PCT No. PCT/EP2019/066022 § 371(c)(1), (2) Date Dec. 12, 2020, PCT Pub. No. WO2019/243337, PCT Pub. Date Dec. 26, 2019.
Claims priority of application No. 20180100264 (GR), filed on Jun. 18, 2018.
Prior Publication US 2021/0161822 A1, Jun. 3, 2021
Int. Cl. A61K 9/19 (2006.01); A61K 31/573 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01)

CPC A61K 9/19 (2013.01) [A61K 31/573 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01)]

5 Claims

1. Pharmaceutical composition in the form of powder for reconstitution for oral administration comprising a mixture of buffered lyophilized methylprednisolone sodium succinate and one or more water-soluble pharmaceutically acceptable excipients, wherein the one or more water-soluble pharmaceutically acceptable excipients are not lyophilized and are selected from the group consisting of from 60% to 75% (w/w), diluent, from 0.1 to 0.5% (w/w), sweetener and from 1 to 6% of (w/w) a lubricant.